Mirum Pharmaceuticals, Inc. (MIRM)
Summary
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
MIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.
Mirum Pharmaceuticals' LIVMARLI Study Hits Key Endpoints in Rare Liver Diseases
Mirum Pharmaceuticals NASDAQ: MIRM said its Phase III EXPAND study of LIVMARLI, or maralixibat, met its primary endpoint and all prespecified secondary endpoints in pediatric patients with cholestatic pruritus associated with ultra-rare cholestatic liver diseases.
Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study
Mirum Pharmaceuticals NASDAQ: MIRM reported positive top-line results from the Phase III portion of its AZURE-1 study evaluating brelovitug for chronic hepatitis delta, saying the investigational antibody met its primary endpoint at 24 weeks and showed a favorable tolerability profile.
Mirum Pharmaceuticals, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 77 | $3,904.6 | $6,256.25 | $2,351.65 | 60.23% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 2,230 | $225,230 | $181,856.5 | -$43,373.5 | -19.26% |
| JB John Brinckerhoff Oak Ridge Investments LLC | 22,408 | $1.47M | $1.82M | $347,062.26 | 23.55% |
| BG Bart Gancher Intech Investment Management LLC | 9,704 | $417,533 | $809,410.64 | $391,877.64 | 93.86% |
| GN Gina Nelson Next Century Growth Investors LLC | 420,213 | $25.8M | $34.34M | $8.54M | 33.1% |
Mirum Pharmaceuticals, Inc. (MIRM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Mirum Pharmaceuticals, Inc. ever had a stock split?
Mirum Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Christopher Peetz CEO | NASDAQ (NMS) Exchange | 604749101 CUSIP |
| US Country | 433 Employees | - Last Dividend | - Last Split | 18 Jul 2019 IPO Date |
Overview
Mirum Pharmaceuticals, Inc. is a pioneering biopharmaceutical company with a sharp focus on the discovery, development, and commercialization of innovative therapies designed to tackle debilitating rare and orphan diseases. Established in 2018 and based in Foster City, California, Mirum Pharmaceuticals has swiftly moved to the forefront of its field, aiming to deliver significant medical advancements for conditions with limited treatment options. The company's strategic approach combines breakthrough science with an unwavering commitment to improving patient outcomes, positioning it as a leader in rare disease therapy development.
Products and Services
- LIVMARLI (maralixibat)
This flagship product stands out as Mirum Pharmaceuticals' premier offering. LIVMARLI is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor. It has gained approval for the treatment of cholestatic pruritus in patients suffering from Alagille syndrome both in the United States and on an international scale. LIVMARLI's innovative mechanism offers new hope for patients grappling with this challenging and rare condition, illustrating the company's dedication to filling critical treatment gaps in rare diseases.
- Cholbam
A cholic acid capsule, Cholbam is another critical component of Mirum Pharmaceuticals' product lineup. The U.S. Food and Drug Administration (FDA) has approved it for use in both pediatric and adult patients who are dealing with bile acid synthesis disorders resulting from single enzyme defects. Furthermore, Cholbam is sanctioned as an adjunctive treatment for various peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome. This approval underscores the company's commitment to addressing unmet needs across a spectrum of rare bile acid disorders.
- Chenodal
Approved for the treatment of radiolucent stones in the gallbladder, Chenodal is a key drug in Mirum Pharmaceuticals' suite of products. Beyond its established use, Chenodal is currently under Phase 3 development for addressing cerebrotendinous xanthomatosis, showcasing the company's ongoing efforts to expand its impact across additional rare diseases through rigorous clinical development.
- Volixibat
Mirum Pharmaceuticals is also advancing Volixibat, a promising therapeutic under investigation. Like LIVMARLI, Volixibat is designed to inhibit the IBAT through an oral, minimally absorbed formulation. Currently in a Phase 2b clinical trial, Volixibat targets the treatment of adult patients with cholestatic liver diseases, signifying the company's continuous pursuit of innovative solutions for complex liver conditions.
Contact Information
